ZFW

OBLON

SPIVAK

McClelland

MAIER

NEUSTADT

P.C.

· ATTORNEYS AT LAW

Docket No.: 246883US0

COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

RE: Application Serial No.: 10/736,711

Applicants: Johann LEBAN, et al. Filing Date: December 17, 2003

Allowed Date: January 24, 2006

For: COMPOUNDS AS ANTI-INFLAMMATORY,

IMMUNOMODULATORY AND ANTI-PROLIFERATORY AGENTS

Group Art Unit: 1621

Examiner: S. Kumar

SIR:

Attached hereto for filing are the following papers:

Amendment Under 37 CFR 1.312

Our check in the amount of \$0.00 is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R 1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Norman F. Oblon

Thomas M. Cunningham

Registration No. 45,394

Customer Number

22850

(703) 413-3000 (phone) (703) 413-2220 (fax)



DOCKET NO: 246883US0

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF

JOHANN LEBAN, ET AL. : EXAMINER: KUMAR, S.

SERIAL NO: 10/736,711 : ALLOWED DATE: JANUARY 24, 2006

FILED: DECEMBER 17, 2003 : GROUP ART UNIT: 1621

FOR: COMPOUNDS AS ANTI-

INFLAMMATORY,

IMMUNOMODULATORY AND ANTI-

PROLIFERATORY AGENTS

AMENDMENT UNDER 37 C.F.R.§1.312

COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

SIR:

This application has been allowed, but the issue fee, as yet, has not been paid. Kindly make the following corrections to the claims.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 13 of this paper.